The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2046-2051

  Wang, Li Hua ^a,b   Yang, Xiao Yi ^a   Zhang, Xiaohu ^a   Mihalic, Kelly ^a   Xiao, Weihua ^a   Farrar, William L ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; CIS ACTING ELEMENT; DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RESPONSE ELEMENT DECOY; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN C FOS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL ACTIVITY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA TRANSCRIPTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE ACTIVITY; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BINDING; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION;

APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DNA, NEOPLASM; ENZYME ACTIVATION; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, FOS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; OLIGONUCLEOTIDES; PHOSPHATES; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0038743150     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Menck, H. R., Cunningham, M. P., Jessup, J. M., Eyre, H. J., Winchester, D. P., Scott-Conner, C. E., and Murphy, G. P. The growth and maturation of the National Cancer Data Base. Cancer (Phila.), 80: 2296-2304, 1997.
2. Jordan, V. C. Selective estrogen receptor modulation: a personal perspective. Cancer Res., 61: 5683-5687, 2001.
3. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell, 1: 465-1470, 1998.
4. Bentrem, D. J., O'Regan, R. M., and Jordan, V. C. New strategies for the treatment of breast cancer. Breast Cancer, 8: 265-274, 2001.
5. Carroll, J. S., Swarbrick, A., Musgrove, E. A., and Sutherland, R. L. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res., 62: 3126-3131, 2002.
6. Joffe, M. Activation of estrogen receptors. Science (Wash. DC), 274: 1285-1286, 1996.
7. McDonnell, D. P., and Norris, J. D. Connections and regulation of the human estrogen receptor. Science (Wash. DC), 296: 1642-1644, 2002.
8. Shang, Y., and Brown, M. Molecular determinants for the tissue specificity of SERMs. Science (Wash. DC), 295: 2465-2468, 2002.
9. Norris, J. D., Paige, L. A., Christensen, D. J., Chang, C. Y., Huacani, M. R., Fan, D., Hamilton, P. T., Fowlkes, D. M., and McDonnell, D. P. Peptide antagonists of the human estrogen receptor. Science (Wash. DC), 285: 744-746, 1999.
10. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond.), 389: 753-758, 1997.
11. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95: 927-937, 1998.
12. Wang, W., Dong, L., Saville, B., and Safe, S. Transcriptional activation of E2F1 gene expression by 17 β-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol. Endocrinol., 13: 1373-1387, 1999.
13. Safe, S. Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm., 62: 231-252, 2001.
14. Dzau, V. J. Transcription factor decoy. Circ. Res., 90: 1234-1236, 2002.
15. Tomita, N., Morishita, R., Tomita, T., and Ogihara, T. Potential therapeutic applications of decoy oligonucleotides. Curr. Opin. Mol. Ther., 4: 166-170, 2002.
16. Ahn, J. D., Morishita, R., Kaneda, Y., Lee, S. J., Kwon, K. Y., Choi, S. Y., Lee, K. U., Park, J. Y., Moon, I. J., Park, J. G., Yoshizumi, M., Ouchi, Y., and Lee, I. K. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ. Res., 90: 1325-1332, 2002.
17. Mann, M. J., Whittemore, A. D., Donaldson, M. C., Belkin, M., Conte, M. S., Polak, J. F., Orav, E. J., Ehsan, A., Dell'Acqua, G., and Dzau, V. J. Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet, 354: 1493-1498, 1999.
18. Ehsan, A., Mann, M. J., Dell'Acqua, G., and Dzau, V. J. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. Thorac. Cardiovasc. Surg., 121: 714-722, 2001.
19. Wang, L. H., Yang, X. Y., Kirken, R. A., Resau, J. H., and Farrar, W. L. Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4driven T(H)2 cell response. Blood, 95: 1249-1257, 2000.
20. Lee, Y. N., Park, Y. G., Choi, Y. H., Cho, Y. S., and Cho-Chung, Y. S. CREtranscription factor decoy oligonucleotide inhibition of MCF-7 breast cancer cells: cross-talk with p53 signaling pathway. Biochemistry, 39: 4863-4868, 2000.
21. Park, Y. G., Park, S., Lim, S. O., Lee, M. S., Ryu, C. K., Kim, I., and Cho-Chung, Y. S. Reduction in cyclin D1/Cdk4/retinoblastoma protein signaling by CRE-decoy oligonucleotide. Biochem. Biophys. Res. Commun., 281: 1213-1219, 2001.
22. Cho, Y. S., Kim, M. K., Cheadle, C., Neary, C., Park, Y. G., Becker, K. G., and Cho-Chung, Y. S. A genomic-scale view of the cAMP response element-enhancer decoy: a tumor target-based genetic tool. Proc. Natl. Acad. Sci. USA, 99: 15626-15631, 2002.
23. Penolazzi, L., Lambertini, E., Aguiari, G., del Senno, L., and Piva, R. Modulation of estrogen receptor gene expression in human breast cancer cells: a decoy strategy with specific PCR-generated DNA fragments. Breast Cancer Res. Treat., 49: 227-235, 1998.
24. Penolazzi, L., Lambertini, E., Aguiari, G., del Senno, L., and Piva, R. Cis element 'decoy' against the upstream promoter of the human estrogen receptor gene. Biochim. Biophys. Acta, 1492: 560-567, 2000.
25. Piva, R., del Senno, L., Lambertini, E., Penolazzi, L., and Nastruzzi, C. Modulation of estrogen receptor gene transcription in breast cancer cells by liposome delivered decoy molecules. J. Steroid Biochem. Mol. Biol., 75: 121-128, 2000.
26. Zwijsen, R. M. L. Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., and Michalides, R. J. A. M. CDK-independent activation of estrogen receptor by cyclin D1. Cell, 88: 405-415, 1997.
27. Wang, L. H., Yang, X. Y., Mihalic, K., Xiao, W., Li, D., and Farrar, W. L. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J. Biol. Chem., 276: 31839-31844, 2001.
28. Wang, L. H., Kirken, R. A., Erwin, R. A., Yu, C. R., and Farrar, W. L. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J. Immunol., 162: 3897-3904, 1999.
29. Frankfurt, O. S., and Krishan, A. Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. J. Immunol. Methods, 253: 133-144, 2001.
30. Yang, X. Y., Wang, L. H., Mihalic, K., Xiao, W., Chen, T., Li, P., Wahl, L. M., and Farrar, W. L. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor γ activated by macrophage-derived 12/15-lipoxygenase ligands. J. Biol. Chem., 277: 3973-3978, 2002.
31. Prall, O. W., Rogan, E. M., and Sutherland, R. L. Estrogen regulation of cell cycle progression in breast cancer cells. J. Steroid Biochem. Mol. Biol., 65: 169-174, 1998.
32. Seth, P., Porter, D., Lahti-Domenici, J., Geng, Y., Richardson, A., and Polyak, K. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res., 62: 4540-4544, 2002.
33. MacGregor, J. I., and Jordan, V. C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev., 50: 151-196, 1998.
34. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res., 51: 162-166, 1991.
35. Pratt, M. A., Krajewski, S., Menard, M., Krajewska, M., Macleod, H., and Reed, J. C. Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2. FEBS Lett., 440: 403-408, 1998.
36. Detre, S., Salter, J., Barnes, D. M., Riddler, S., Hills, M., Johnston, S. R., Gillett, C., A'Hern, R., and Dowsett, M. Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. Int. J. Cancer, 81: 309-313, 1999.
37. Klinge, C. M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res., 29: 2905-2919, 2001.
38. Driscoll, M. D., Sathya, G., Muyan, M., Klinge, C. M., Hilf, R., and Bambara, R. A. Sequence requirements for estrogen receptor binding to estrogen response elements. J. Biol. Chem., 273: 29321-29330, 1998.
39. Klein-Hitpass, L., Schorpp, M., Wagner, U., and Ryffel, G. U. An estrogen-responsive element derived from the 5′ flanking region of the xenopus vitellogenin A2 gene functions in transfected human cells. Cell, 46: 1053-1061, 1986.
40. Weisz, A., and Rosales, R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res., 18: 5097-5106, 1990.
41. Hyder, S. M., Stancel, G. M., Nawaz, Z., McDonnell, D. P., and Loose-Mitchell, D. S. Identification of an estrogen response element in the 3′-flanking region of the murine c-fos protooncogene. J. Biol. Chem., 267: 18047-18054, 1992.
42. Loose-Mitchell, D. S., Chiappetta, C., and Stancel, G. M. Estrogen regulation of c-fos messenger ribonucleic acid. Mol. Endocrinol., 2: 946-951, 1988.
43. Weisz, A., and Bresciani, F. Estrogen induces expression of c-fos and c-myc protooncogenes in rat uterus. Mol. Endocrinol., 2: 816-824, 1988.
44. Duan, R., Xie, W., Li, X., McDougal, A., and Safe, S. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun., 294: 384-394, 2002.
45. Collins, P., and Webb, C. Estrogen hits the surface. Nat. Med., 5: 1130-1131, 1999.
46. Mann, M. J., and Dzau, V. J. Therapeutic applications of transcription factor decoy oligonucleotides. J. Clin. Investig., 106: 1071-1075, 2000.
47. Mann, M. J., Gibbons, G. H., Hutchinson, H., Poston, R. S., Hoyt, E. G., Robbins, R. C., and Dzau, V. J. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc. Natl. Acad. Sci. USA, 96: 6411-6416, 1999.
48. Morishita, R., Aoki, M., and Kaneda, Y. Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs? Curr. Drug Targets, 1: 15-23, 2000.
49. Morishita, R., Gibbons, G. H., Horiuchi, M., Ellison, K. E., Nakama, M., Zhang, L., Kaneda, Y., Ogihara, T., and Dzau, V. J. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA, 92: 5855-5859, 1995.
50. Morishita, R., Sugimoto, T., Aoki, M., Kida, I., Tomita, N., Moriguchi, A., Maeda, K., Sawa, Y., Kaneda, Y., Higaki, J., and Ogihara, T. In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction. Nat. Med., 3: 894-899, 1997.
51. Hyder, S. M., Nawaz, Z., Chiappetta, C., Yokoyama, K., and Stancel, G. M. The protooncogene c-jun contains an unusual estrogen-inducible enhancer within the coding sequence. J. Biol. Chem., 270: 8506-8513, 1995.
52. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. Differential ligand activation of estrogen receptors ERα and ERβ at API sites. Science (Wash. DC), 277: 1508-1510, 1997.
53. Dubik, D., Watson, P. H., Venditti, M., and Shiu, R. P. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene, 7: 1587-1594, 1992.
54. Hyder, S. M., Shipley, G. L., and Stancel, G. M. Estrogen action in target cells: selective requirements for activation of different hormone response elements. Mol. Cell. Endocrinol., 112: 35-43, 1995.
55. Crowe, D. L., Brown, T. N., Kim, R., Smith, S. M., and Lee, M. K. A c-fos/estrogen receptor fusion protein promotes cell cycle progression and proliferation of human cancer cell lines. Mol. Cell. Biol. Res. Commun., 3: 243-248, 2000.
56. Lee, H. W., and Eghbali-Webb, M. Estrogen enhances proliferative capacity of cardiac fibroblasts by estrogen receptor- and mitogen-activated protein kinase-dependent pathways. J. Mol. Cell. Cardiol., 30: 1359-1368, 1998.
57. Castoria, G., Barone, M. V., Di Domenico, M., Bilancio, A., Ametrano, D., Migliaccio, A., and Auricchio, F. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J., 18: 2500-2510, 1999.
58. Lobenhofer, E. K., and Marks, J. R. Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity. J. Steroid Biochem. Mol. Biol., 75: 11-20, 2000.
59. Keller, H., Givel, F., Perroud, M., and Wahli, W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol. Endocrinol., 9: 794-804, 1995.
60. Nunez, S. B., Medin, J. A., Braissant, O., Kemp, L., Wahli, W., Ozato, K., and Segars, J. H. Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol. Cell. Endocrinol., 127: 27-40, 1997.
61. Wang, X., and Kilgore, M. W. Signal cross-talk between estrogen receptor α and β and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol. Cell. Endocrinol., 194: 123-133, 2002.
62. 1 cell cycle regulators. Biochem. Biophys. Res. Commun., 286: 916-922, 2001.